Abstract

22011 Background: The aim of our study was to investigate pretreatment serum CA-125 concentration as a prognostic factor in pts with EOC. Methods: A retrospective analysis was conducted on 219 pts ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
409 Serum Ca125 in patients with endometrial cancer
T Yasui ... M Yamauchi
-
T Yasui, et. al.T Yasui ... M Yamauchi
01 Sep 2019
Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.
Qingyi Wang ... Xiaoling Feng
Frontiers in oncology | VOL. 12
Qingyi Wang, et. al.Qingyi Wang ... Xiaoling Feng
07 Apr 2022
Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial
L Randall-Whitis ... B J Monk
Journal of Clinical Oncology | VOL. 27
L Randall-Whitis, et. al.L Randall-Whitis ... B J Monk
20 May 2009
A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis.
Yuan Zurong ... Feng Dianxu
Pancreas | VOL. 25
Yuan Zurong, et. al.Yuan Zurong ... Feng Dianxu
01 Nov 2002
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers